Pfizer and Cipla have separately committed to expanding access to affordable oncology drugs in sub-Saharan Africa in collaboration with the American Cancer Society and the Clinton Health Access Initiative. The public-private alliances are expected to enable procurement of these medicines for the African nations at significant savings, which Cipla tells Scrip could be in the region of 20-30% initially.
The American Cancer Society (ACS) and the Clinton Health Access Initiative (CHAI) are hoping to rewrite the script for cancer patients in six sub-Saharan African nations, akin to the drug access initiatives taken in the HIV/AIDS segment several years ago.
ACS and CHAI have now sewn up what they termed as “ground-breaking” market access agreements with Pfizer Inc. and...
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
